Cargando…
The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75
Lens-epithelium-derived growth-factor (LEDGF/p75)-binding site on HIV-1 integrase (IN), is an attractive target for antiviral chemotherapy. Small-molecule compounds binding to this site are referred as LEDGF-IN inhibitors (LEDGINs). In this study, compound libraries were screened to identify new inh...
Autores principales: | Zhang, Da-Wei, Yan, Hao-Li, Xu, Xiao-Shuang, Xu, Lei, Yin, Zhi-Hui, Chang, Shan, Luo, Heng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7170385/ https://www.ncbi.nlm.nih.gov/pubmed/32228103 http://dx.doi.org/10.1080/14756366.2020.1743282 |
Ejemplares similares
-
The Lentiviral Integrase Binding Protein LEDGF/p75 and HIV-1 Replication
por: Engelman, Alan, et al.
Publicado: (2008) -
Modulation of the intrinsic chromatin binding property of HIV-1 integrase by LEDGF/p75
por: Lapaillerie, Delphine, et al.
Publicado: (2021) -
HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor
por: Wang, Hao, et al.
Publicado: (2012) -
Analysis of LEDGF/p75 expression regulation
por: Desfarges, Sébastien, et al.
Publicado: (2009) -
LEDGF/p75 interacts with divergent lentiviral integrases and modulates their enzymatic activity in vitro
por: Cherepanov, Peter
Publicado: (2007)